Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb

被引:12
作者
Kleiman, NS
Granger, CB
White, HD
Armstrong, P
Ardissino, D
Van de Werf, F
Zoldeyhi, P
Thompson, TD
Califf, RM
Topol, EJ
机构
[1] Methodist Hosp, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Green Lane Hosp, Auckland 3, New Zealand
[4] Duke Univ, Clin Res Inst, Durham, NC USA
[5] Walter C Mackenzie Hlth Ctr, Edmonton, AB, Canada
[6] Univ Pavia, I-27100 Pavia, Italy
[7] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[8] Univ Texas, Hlth Sci Ctr, Houston, TX USA
[9] Cleveland Clin Fdn, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0002-8703(99)70455-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A large proportion of deaths among patients with myocardial infarction occurs within the first 24 hours after presentation. It is not clear whether this phenomenon is also true of patients without ST-segment elevation who may or may not have infarction at the time of presentation. Thrombin activity may also be greatest during the first 24 hours after plaque rupture. Accordingly, this study was designed to examine the pattern of early ischemic events among patients with acute coronary syndromes and to determine whether the direct thrombin inhibitor desirudin (r-hirudin) would be most effective during this period. Methods and Results Among the 11,142 patients enrolled in GUSTO-II, death or (re)infarction occurred within 24 hours in 210 patients (1.7%), representing 19% of the 1135 deaths that had occurred by 30 days. Death or (re)infarction occurred within 24 hours in 113 patients (2.7%) with ST-segment elevation and in 97 patients without ST-segment elevation (1.2%, P < .001), representing 26% and 14% of the 30-day event rates, respectively, for the 2 enrollment strata. Among patients with ST-segment elevation, most of these events were deaths, whereas among patients without ST-segment elevation, most events were (re)infarctions. Death or (re)infarction by 24 hours occurred in 80 (1.3%) patients treated with desirudin and 130 (2.1%) patients treated with heparin (P = .01). This finding predominantly consisted of prevention of death among patients with ST-segment elevation and of (re)infarction among patients without ST-segment elevation. Conclusions These findings have important implications for early triage of patients with acute coronary syndromes and for the development of new therapies directed at stabilizing the unstable atherosclerotic plaque.
引用
收藏
页码:12 / 23
页数:12
相关论文
共 39 条
[1]   Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions [J].
Abdelmeguid, AE ;
Topol, EJ ;
Whitlow, PL ;
Sapp, SK ;
Ellis, SG .
CIRCULATION, 1996, 94 (07) :1528-1536
[2]  
AGUIRRE F, 1993, CIRCULATION, V88, P201
[3]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[4]   Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes [J].
Antman, EM ;
Tanasijevic, MJ ;
Thompson, B ;
Schactman, M ;
McCabe, CH ;
Cannon, CP ;
Fischer, GA ;
Fung, AY ;
Thompson, C ;
Wybenga, D ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (18) :1342-1349
[5]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[6]   Thrombin activity and early outcome in unstable angina pectoris [J].
Ardissino, D ;
Merlini, PA ;
Gamba, G ;
Barberis, P ;
Demicheli, G ;
Testa, S ;
Colombi, E ;
Poli, A ;
Fetiveau, R ;
Montemartini, C .
CIRCULATION, 1996, 93 (09) :1634-1639
[7]   EVALUATION OF PARADOXIC BENEFICIAL-EFFECTS OF SMOKING IN PATIENTS RECEIVING THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - MECHANISM OF THE SMOKERS PARADOX FROM THE GUSTO-I TRIAL, WITH ANGIOGRAPHIC INSIGHTS [J].
BARBASH, GI ;
REINER, J ;
WHITE, HD ;
WILCOX, RG ;
ARMSTRONG, PW ;
SADOWSKI, Z ;
MORRIS, D ;
AYLWARD, P ;
WOODLIEF, LH ;
TOPOL, EJ ;
CALIFF, RM ;
ROSS, AM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (05) :1222-1229
[8]   TREATMENT WITH BIVALIRUDIN (HIRULOG) AS COMPARED WITH HEPARIN DURING CORONARY ANGIOPLASTY FOR UNSTABLE OR POSTINFARCTION ANGINA [J].
BITTL, JA ;
STRONY, J ;
BRINKER, JA ;
AHMED, WH ;
MECKEL, CR ;
CHAITMAN, BR ;
MARAGANORE, J ;
DEUTSCH, E ;
ADELMAN, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (12) :764-769
[9]   EFFECT OF HEPARIN ON CORONARY ARTERIAL PATENCY AFTER THROMBOLYSIS WITH TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION [J].
BLEICH, SD ;
NICHOLS, TC ;
SCHUMACHER, RR ;
COOKE, DH ;
TATE, DA ;
TEICHMAN, SL .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (20) :1412-1417
[10]  
BRAUNWALD E, 1994, CIRCULATION, V89, P1545